INSM
155.36 USD
-2.27%
Today
-3.03%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Insmed Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0191%
Overnight Fees Sell
0.0024%
Market Cap
34.45B
Avg Daily Volume
3.00M
52 Week High
212.75 USD
52 Week Low
60.4 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01910% | $(0.191) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Top News
AmAirlines
-0.53%
AbbottLabs
-2.35%
Aehr.Systems
+1.44%
AmgenInc
+0.94%
Amarin
-0.91%
Apollo
-2.49%
AxonEnterprise
-1.56%
BOAmerica
-0.13%
Beyond.Inc
-1.68%
BookingHld
-1.76%
BioXcel
-0.95%
Blackstone
-1.66%
Coeur
+2.59%
CFIndustries
+1.73%
Chegg
-6.02%
Chewy
-2.86%
Clean.Spark
-2.25%
Coinbase
-1.15%
Chevron
-0.53%
Delta
-0.16%
Deere
-1.20%
DR_Horton
+0.35%
Devon
+0.23%
ElancoAnimal
-1.50%
Elevance-Health-Inc
-2.02%
Expedia
-1.01%
Freeport_Mcmoran
+2.43%
GATX_Corp
+1.37%
Greenbrier
-2.34%
GileadSci
-2.26%
GoldmanSachs
+0.80%
HimsandHers.Inc
-0.41%
Hecla.Mining
+0.73%
Humana
-2.52%
IDEXXLab
-3.76%
Insmed
-3.03%
JBHunt
+0.86%
JPMorgan
+0.09%
KKR&Co
-1.65%
Lennar
+0.51%
Levi.Strauss
+0.00%
Southwest
-1.74%
Mosaic
-2.06%
MicroStrategy
-0.76%
NorwegianCruise
+1.06%
NewmontM
+2.35%
Novavax
-5.52%
Opko
-1.74%
Occidental
+0.00%
PulteGroup
-1.54%
ProQR.Therapeutics
-6.19%
SouthernCopper
+2.32%
Scorpio.Tankers
-2.29%
TollBrothers
-0.04%
UnitySoftware
+0.33%
UnitedCon
-1.32%
UnitedHlt
-0.66%
ViaSat
+0.92%
Westinghouse
-1.21%
WellsFargo
-0.61%
ExxonMobil
-1.24%
ZoetisInc
-1.82%
BUZZ-U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
reuters.com
2d ago
AmAirlines
-0.53%
AbbottLabs
-2.35%
Aehr.Systems
+1.44%
AmgenInc
+0.94%
Amarin
-0.91%
Apollo
-2.49%
AxonEnterprise
-1.56%
BOAmerica
-0.13%
Beyond.Inc
-1.68%
BookingHld
-1.76%
BioXcel
-0.95%
Blackstone
-1.66%
Coeur
+2.59%
CFIndustries
+1.73%
Clean.Spark
-2.25%
Coinbase
-1.15%
Chevron
-0.53%
Delta
-0.16%
Deere
-1.20%
Devon
+0.23%
ElancoAnimal
-1.50%
Elevance-Health-Inc
-2.02%
Expedia
-1.01%
Freeport_Mcmoran
+2.43%
GATX_Corp
+1.37%
Greenbrier
-2.34%
GileadSci
-2.26%
GoldmanSachs
+0.80%
Hecla.Mining
+0.73%
Humana
-2.52%
IDEXXLab
-3.76%
Insmed
-3.03%
JBHunt
+0.86%
JPMorgan
+0.09%
KKR&Co
-1.65%
Levi.Strauss
+0.00%
Southwest
-1.74%
Mosaic
-2.06%
MicroStrategy
-0.76%
NorwegianCruise
+1.06%
NewmontM
+2.35%
Novavax
-5.52%
Opko
-1.74%
Occidental
+0.00%
SouthernCopper
+2.32%
Scorpio.Tankers
-2.29%
UnitySoftware
+0.33%
UnitedCon
-1.32%
ViaSat
+0.92%
Westinghouse
-1.21%
WellsFargo
-0.61%
ExxonMobil
-1.24%
ZoetisInc
-1.82%
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
reuters.com
2d ago
US Equity Markets Mixed After Federal Reserve Chair Powell's Reassuring Comments on Inflation
finance.yahoo.com
1w ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
